The Latest Cardiac and Vascular News
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. “I want to […]
SUNNYVALE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2024 by conference call on Wednesday, November 13, 2024 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.
LAS VEGAS, Nov. 5, 2024 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final two rounds of Late-Breaking Clinical Trials presented at…
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced the final 36-month results of the DETOUR2 Study. The DETOUR System offers a unique approach […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, a leading artificial intelligence (AI)-driven health technology company, announced that the Centers for Medicare & Medicaid Services (CMS) has included its low ejection fraction (LEF) ECG-AI™ technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule under […]
Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health system ALAMEDA, Calif., Nov. 5, 2024…
Brings over 30 years of experience in cardiovascular clinical research, business development, training, education, and medical affairs Strengthens Xeltis’ leadership team following IDE approval for initiation of US pivotal study for aXess™, its restorative vascular access conduit…
LAS VEGAS, Nov. 4, 2024 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first two rounds of Late-Breaking Clinical Trials presented at…
Comparative data and systematic literature review released at VIVA 2024 show breadth and depth of data supporting atherectomy as a treatment for peripheral arterial disease Medtronic, the global leader in healthcare technology, today announced results from two studies evaluating the […]
Novel Intravascular Lithotripsy (IVL) catheter demonstrates ability to modify calcium safely, enabling treatment and crossing of tightly-stenosed lower limb lesions Technology has received U.S. FDA clearance for patients with peripheral arterial disease LAS VEGAS, Nov. 4, 2024…
